» Articles » PMID: 28953640

Comparative Effectiveness and Acceptability of the FDA-licensed Proton Pump Inhibitors for Erosive Esophagitis: A PRISMA-compliant Network Meta-analysis

Overview
Specialty General Medicine
Date 2017 Sep 28
PMID 28953640
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study compared the effectiveness and acceptability of all Food and Drug Administration (FDA)-recommended dose proton pump inhibitors (PPIs) in erosive esophagitis (EE): Dexlansoprazole 60 mg, Esomeprazole 40 mg, Esomeprazole 20 mg, Pantoprazole 40 mg, Lansoprazole 30 mg, Rabeprazole 20 mg, Omeprazole 20 mg.

Methods: A systematic literature search was performed using PubMed, Embase, and Cochrane Library. Totally, 25 randomized controlled trials (RCTs) met study selection criteria and were incorporated in this network meta-analysis (NMA) study.

Results: For the NMA, eligible RCTs of adults with EE verified by endoscopic examination were randomly assigned to the licensed PPIs at least 4 weeks of continuous therapy. The primary efficacy outcome was the endoscopic healing rates at 4 and 8 weeks. Heartburn relief rates were a secondary efficacy outcome. The rates of withdrawal were analyzed as a safety outcome. In comparison to the common comparator omeprazole 20 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [odds ratio (OR), 1.46 (95% confidence interval, 95% CI, 1.24-1.71)] and 8 weeks [1.58 (1.29-1.92)], and improved the heartburn relief rates [1.29 (1.07-1.56)]. In comparison to lansoprazole 30 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [1.30 (1.10-1.53)] and 8 weeks [1.37 (1.13-1.67)], and improved the heartburn relief rates [1.29 (1.03-1.62)]. In terms of acceptability, only dexlansoprazole 60 mg had significantly more all-cause discontinuation than omeprazole 20 mg [1.54 (1.03-2.29)], pantoprazole 40 mg [1.68 (1.08-2.63)], and lansoprazole 30 mg [1.38 (1.02-1.88)].

Conclusion: The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief. Esomeprazole 40 mg, pantoprazole 40 mg, esomeprazole 20 mg, and lansoprazole 30 mg showed more benefits in effectiveness and acceptability than other interventions.

Citing Articles

Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements.

Armstrong D, Hungin A, Kahrilas P, Sifrim D, Moayyedi P, Vaezi M Aliment Pharmacol Ther. 2024; 61(4):636-650.

PMID: 39740235 PMC: 11754941. DOI: 10.1111/apt.18420.


Comparative Efficacy of Dexlansoprazole, Pantoprazole, Esomeprazole, and Rabeprazole in Achieving Optimal 24-Hour Intragastric pH Control: A Randomized Crossover Study Using Ambulatory pH Monitoring.

Jalihal U, Mahapatra J, Kumar A, Bharadwaj T, Singh H, Mehta V Cureus. 2024; 16(10):e71418.

PMID: 39539895 PMC: 11558283. DOI: 10.7759/cureus.71418.


GERD: Latest update on acid-suppressant drugs.

Al-Frejat Z, Martini N, Esper A, Al-Frejat D, Younes S, Hanna M Curr Res Pharmacol Drug Discov. 2024; 7:100198.

PMID: 39282236 PMC: 11393603. DOI: 10.1016/j.crphar.2024.100198.


Lansoprazole plus levosulpiride versus esomeprazole in participants with gastroesophageal reflux disease and erosive esophagitis: a double blinded randomized control trial.

Umer M, Mejia Crespo W, Dugan S, Javed H, Suleman M, Afzal M Ann Med Surg (Lond). 2023; 85(10):4866-4876.

PMID: 37811050 PMC: 10553095. DOI: 10.1097/MS9.0000000000001235.


Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis.

He J, Gao Y, Bai G, Wang J, Sun Y J Comp Eff Res. 2023; 12(8):e220165.

PMID: 37470274 PMC: 10508317. DOI: 10.57264/cer-2022-0165.


References
1.
Halpern R, Kothari S, Fuldeore M, Zarotsky V, Porter V, Dabbous O . GERD-related health care utilization, therapy, and reasons for transfer of GERD patients between primary care providers and gastroenterologists in a US managed care setting. Dig Dis Sci. 2009; 55(2):328-37. PMC: 2804792. DOI: 10.1007/s10620-009-0927-9. View

2.
Richter J, Bochenek W . Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol. 2000; 95(11):3071-80. DOI: 10.1111/j.1572-0241.2000.03254.x. View

3.
Mee A, ROWLEY J . Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther. 1996; 10(5):757-63. DOI: 10.1046/j.1365-2036.1996.56198000.x. View

4.
Rohss K, Lind T, Wilder-Smith C . Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol. 2004; 60(8):531-9. DOI: 10.1007/s00228-004-0804-6. View

5.
Sharma V, Leontiadis G, Howden C . Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther. 2001; 15(2):227-31. DOI: 10.1046/j.1365-2036.2001.00904.x. View